YI Quote, Financials, Valuation and Earnings

Concord Medical Services Holdings has a net margin of -0.52% compared to 111's net margin of --. 111's return on equity of -21.67% beat Concord Medical Services Holdings's return on equity of -19.78%.

111 has a consensus price target of --, signalling upside risk potential of 651.45%. On the other hand Concord Medical Services Holdings has an analysts' consensus of -- which suggests that it could grow by 59.58%. Given that 111 has higher upside potential than Concord Medical Services Holdings, analysts believe 111 is more attractive than Concord Medical Services Holdings.

111 has a beta of 0.472, which suggesting that the stock is 52.823% less volatile than S&P 500. In comparison Concord Medical Services Holdings has a beta of -0.837, suggesting its less volatile than the S&P 500 by 183.673%.

111 has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Concord Medical Services Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. 111 pays -- of its earnings as a dividend. Concord Medical Services Holdings pays out -- of its earnings as a dividend.

111 quarterly revenues are $534.8M, which are larger than Concord Medical Services Holdings quarterly revenues of --. 111's net income of -$2.8M is higher than Concord Medical Services Holdings's net income of --. Notably, 111's price-to-earnings ratio is -- while Concord Medical Services Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for 111 is 0.03x versus 0.62x for Concord Medical Services Holdings. Usually stocks with elevated PS ratios are considered overvalued.

China Pharma Holding has a net margin of -0.52% compared to 111's net margin of -101.61%. 111's return on equity of -21.67% beat China Pharma Holding's return on equity of -66.27%.

111 has a consensus price target of --, signalling upside risk potential of 651.45%. On the other hand China Pharma Holding has an analysts' consensus of -- which suggests that it could fall by --. Given that 111 has higher upside potential than China Pharma Holding, analysts believe 111 is more attractive than China Pharma Holding.

111 has a beta of 0.472, which suggesting that the stock is 52.823% less volatile than S&P 500. In comparison China Pharma Holding has a beta of 0.854, suggesting its less volatile than the S&P 500 by 14.629%.

111 has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. China Pharma Holding offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. 111 pays -- of its earnings as a dividend. China Pharma Holding pays out -- of its earnings as a dividend.

111 quarterly revenues are $534.8M, which are larger than China Pharma Holding quarterly revenues of $1.1M. 111's net income of -$2.8M is lower than China Pharma Holding's net income of -$1.1M. Notably, 111's price-to-earnings ratio is -- while China Pharma Holding's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for 111 is 0.03x versus 0.81x for China Pharma Holding. Usually stocks with elevated PS ratios are considered overvalued.

Sinovac Biotech has a net margin of -0.52% compared to 111's net margin of --. 111's return on equity of -21.67% beat Sinovac Biotech's return on equity of -1.05%.

111 has a consensus price target of --, signalling upside risk potential of 651.45%. On the other hand Sinovac Biotech has an analysts' consensus of -- which suggests that it could fall by --. Given that 111 has higher upside potential than Sinovac Biotech, analysts believe 111 is more attractive than Sinovac Biotech.

111 has a beta of 0.472, which suggesting that the stock is 52.823% less volatile than S&P 500. In comparison Sinovac Biotech has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

111 has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sinovac Biotech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. 111 pays -- of its earnings as a dividend. Sinovac Biotech pays out -328.35% of its earnings as a dividend.

111 quarterly revenues are $534.8M, which are larger than Sinovac Biotech quarterly revenues of --. 111's net income of -$2.8M is higher than Sinovac Biotech's net income of --. Notably, 111's price-to-earnings ratio is -- while Sinovac Biotech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for 111 is 0.03x versus 1.49x for Sinovac Biotech. Usually stocks with elevated PS ratios are considered overvalued.

Zai Lab has a net margin of -0.52% compared to 111's net margin of -74.89%. 111's return on equity of -21.67% beat Zai Lab's return on equity of -34.09%.

111 has a consensus price target of --, signalling upside risk potential of 651.45%. On the other hand Zai Lab has an analysts' consensus of $54.46 which suggests that it could grow by 86.26%. Given that 111 has higher upside potential than Zai Lab, analysts believe 111 is more attractive than Zai Lab.

111 has a beta of 0.472, which suggesting that the stock is 52.823% less volatile than S&P 500. In comparison Zai Lab has a beta of 1.037, suggesting its more volatile than the S&P 500 by 3.742%.

111 has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zai Lab offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. 111 pays -- of its earnings as a dividend. Zai Lab pays out -- of its earnings as a dividend.

111 quarterly revenues are $534.8M, which are larger than Zai Lab quarterly revenues of $109.1M. 111's net income of -$2.8M is higher than Zai Lab's net income of -$81.7M. Notably, 111's price-to-earnings ratio is -- while Zai Lab's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for 111 is 0.03x versus 7.25x for Zai Lab. Usually stocks with elevated PS ratios are considered overvalued.